Updated: After long slog, AstraZeneca finally gets CTLA-4 drug over finish line
It took years of sorting through failed trials to find the right dosing regimen, but AstraZeneca has finally landed an approval for its CTLA-4 inhibitor.
Imjudo — better known as tremelimumab, or treme — joins Bristol Myers Squibb’s Yervoy as the only FDA-approved CTLA-4 drug. The initial OK covers its use in unresectable hepatocellular carcinoma, the most common type of liver cancer.
AstraZeneca EVP of Oncology Dave Fredrickson told Endpoints News that the cost of the new Imjudo-Imfinzi regimen will be published in a few days, but that it will be “comparable” to other approved combination treatments in the liver cancer space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.